Perspectives on the Systemic Staging in Newly Diagnosed Breast Cancer.

Breast neoplasm Cancer staging Metastasis Positron emission tomography de novo

Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
08 2021
Historique:
received: 08 10 2020
revised: 06 03 2021
accepted: 23 03 2021
pubmed: 9 5 2021
medline: 20 1 2022
entrez: 8 5 2021
Statut: ppublish

Résumé

Breast cancer is a complex disease, and accurate systemic staging is an essential aspect of the evaluation of a patient with newly diagnosed breast cancer. Considering that the chance of having metastatic disease at breast cancer diagnosis is different in each patient and depends on a variety of anatomic and biologic factors, it is crucial to understand that some populations may benefit from more intensive staging because their pretest probability of metastatic disease is higher than that of the average patient. Identifying these patients with de novo stage IV breast cancer is associated with substantial prognostic and therapeutic implications. Unfortunately, recent advances in understanding breast cancer heterogeneity and molecular biology have not been incorporated in the international guidelines and recommendations about imaging examinations for detecting de novo metastatic breast cancer. This review article discusses important issues regarding the rationale for performing systemic staging, addresses current and innovative imaging methods, and proposes an algorithm for systemic staging in patients with newly diagnosed breast cancer.

Identifiants

pubmed: 33962905
pii: S1526-8209(21)00065-3
doi: 10.1016/j.clbc.2021.03.010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

309-316

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Tomás Reinert (T)

Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Oncoclinicas, Porto Alegre, Brazil. Electronic address: tomasreinert@hotmail.com.

Alessandra Borba Anton de Souza (ABA)

Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.

Mahira Lopes Rosa (ML)

Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.

Sabrina Richter Bedin (SR)

Oncoclinicas, Porto Alegre, Brazil.

Carlos Henrique Barrios (CH)

Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Oncoclinicas, Porto Alegre, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH